RPHM Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.

$2.12  +0.09 (4.43%)
As of 05/26/2022 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/09/2021
Outstanding shares:  24,458,550
Average volume:  122,974
Market cap:   $49,650,856
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMHR7T5
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.38
PS ratio:   0.00
Return on equity:   -33.69%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy